DE69737562D1 - Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis - Google Patents

Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis

Info

Publication number
DE69737562D1
DE69737562D1 DE69737562T DE69737562T DE69737562D1 DE 69737562 D1 DE69737562 D1 DE 69737562D1 DE 69737562 T DE69737562 T DE 69737562T DE 69737562 T DE69737562 T DE 69737562T DE 69737562 D1 DE69737562 D1 DE 69737562D1
Authority
DE
Germany
Prior art keywords
subject
treating
ischemic disorder
sufficient
comprises administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737562T
Other languages
English (en)
Other versions
DE69737562T2 (de
Inventor
David J Pinsky
David Stern
Ann Marie Schmidt
Eric A Rose
E Sander Connoly
Robert A Solomon
Charles J Prestigiacomo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of DE69737562D1 publication Critical patent/DE69737562D1/de
Application granted granted Critical
Publication of DE69737562T2 publication Critical patent/DE69737562T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
DE69737562T 1996-09-27 1997-09-25 Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis Expired - Lifetime DE69737562T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72144796A 1996-09-27 1996-09-27
US721447 1996-09-27
PCT/US1997/017229 WO1998013058A1 (en) 1996-09-27 1997-09-25 Methods for treating an ischemic disorder and improving stroke outcome

Publications (2)

Publication Number Publication Date
DE69737562D1 true DE69737562D1 (de) 2007-05-16
DE69737562T2 DE69737562T2 (de) 2007-12-27

Family

ID=24898028

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737562T Expired - Lifetime DE69737562T2 (de) 1996-09-27 1997-09-25 Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis

Country Status (10)

Country Link
EP (2) EP1829550A3 (de)
JP (1) JP2001501612A (de)
AT (1) ATE358492T1 (de)
AU (1) AU4594297A (de)
CA (1) CA2266640C (de)
DE (1) DE69737562T2 (de)
DK (1) DK0951292T3 (de)
ES (1) ES2285740T3 (de)
PT (1) PT951292E (de)
WO (1) WO1998013058A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712226A3 (de) * 1996-04-05 2007-03-21 The General Hospital Corporation Behandlung von einem Hemoglobinopathy
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
WO1999049803A1 (en) * 1998-04-01 1999-10-07 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
FR2816212A1 (fr) * 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
US20030198639A1 (en) * 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
MXPA03012031A (es) * 2001-06-21 2005-07-01 Univ Yale El monoxido de carbono mejoraresultados en transplantes de tejido y organo y suprime apoptosis.
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
AU2003211102B2 (en) 2002-02-13 2010-03-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
JP4588325B2 (ja) 2002-04-15 2010-12-01 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション イレウスの治療方法
US8097585B2 (en) 2002-04-15 2012-01-17 Beth Israel Deaconess Medical Center, Inc. Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation
PL374241A1 (en) 2002-04-15 2005-10-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
MXPA04011426A (es) 2002-05-17 2005-10-19 Univ Yale Metodo para tratar la hepatitis.
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
US20040228930A1 (en) * 2002-11-07 2004-11-18 Billiar Timothy R. Treatment for hemorrhagic shock
CN1901795B (zh) 2003-10-22 2014-03-26 弗雷德哈钦森癌症研究中心 用于在细胞，组织，器官，和有机体中诱导停滞的方法，组合物和装置
EP1552840A1 (de) * 2004-01-07 2005-07-13 Aga Ab Mischung aus Xenon und Kohlenmonoxyd zum Schutz von Zellen
LT2264043T (lt) 2005-09-02 2017-12-11 Glycomimetics, Inc. Heterobifunkciniai pan-selektino inhibitoriai
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
EP2356224A4 (de) * 2008-11-10 2012-12-26 Sinai School Medicine Verfahren zur hemmung von gewebeschäden in zusammenhang mit entzündungen durch hemmen der neutrophilaktivität
CN101732348B (zh) * 2008-11-11 2015-01-14 威世药业（如皋）有限公司 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
PT2699242T (pt) 2011-04-19 2018-01-22 Alfama Inc Moléculas de libertação de monóxido de carbono e utilizações das mesmas
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
AU2012358150B2 (en) 2011-12-22 2017-07-20 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
WO2013162078A1 (ja) * 2012-04-27 2013-10-31 学校法人日本大学 上皮及び内皮損傷の治療剤
CN104837492B (zh) 2012-12-07 2018-04-27 糖模拟物有限公司 使用e-选择素拮抗剂动员造血细胞的化合物、组合物和方法
EP3227310B1 (de) 2014-12-03 2019-07-31 GlycoMimetics, Inc. Heterobifunktionelle inhibitoren von e-selektinen und cxcr4-chemokinrezeptoren
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
EP3596096A1 (de) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl-derivate als e-selectin-antagonisten
EP3717013A1 (de) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Verfahren zur mobilisierung von knochenmarkinfiltrierenden lymphozyten und deren verwendung
EP3732186A1 (de) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunktionale inhibitoren von e-selektin und galectin-3
EP3761994A1 (de) 2018-03-05 2021-01-13 GlycoMimetics, Inc. Verfahren zur behandlung akuter myeloischer leukämie und verwandter zustände
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
JP3512111B2 (ja) * 1992-05-22 2004-03-29 モンタナ ステイト ユニバーシティ 多重付着分子に対する特異性を有する抗体
US5591835A (en) * 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
EP0671951A4 (de) * 1992-12-01 1997-05-21 Protein Design Labs Inc Humanisierte antikörper, die mit 1-selektine reagieren.
EP0747059A1 (de) * 1994-01-28 1996-12-11 Japan Tobacco Inc. Ein antientzündungsmittel enthaltend monoklonale antikörper mit reaktivität gegen sialyl-lewis x-zuckerketten, die aus der zellmembran von hämangioendothel-zellen stammen
DE4403057C1 (de) * 1994-02-02 1994-12-08 Biotest Pharma Gmbh Thrombozytenstabilisierende Faktor IX-Fragmente, deren Herstellung sowie sie enthaltende Arzneimittel
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung

Also Published As

Publication number Publication date
EP1829550A3 (de) 2008-04-30
PT951292E (pt) 2007-06-18
CA2266640A1 (en) 1998-04-02
CA2266640C (en) 2011-05-24
JP2001501612A (ja) 2001-02-06
ES2285740T3 (es) 2007-11-16
DK0951292T3 (da) 2007-08-13
EP0951292B1 (de) 2007-04-04
ATE358492T1 (de) 2007-04-15
WO1998013058A1 (en) 1998-04-02
EP0951292A1 (de) 1999-10-27
DE69737562T2 (de) 2007-12-27
EP1829550A2 (de) 2007-09-05
AU4594297A (en) 1998-04-17
EP0951292A4 (de) 2004-08-04

Similar Documents

Publication Publication Date Title
DE69737562D1 (de) Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
DE59807122D1 (de) Verwendung von fumarsäurederivaten zur behandlung von autoimmunerkrankungen
ATE241351T1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
DE69711894D1 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE207759T1 (de) Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels
ATE481970T1 (de) Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
EE05025B1 (et) Fumaarhappe derivaadid kasutamiseks transplantaadivastase reaktsiooni raviks
ATE311876T1 (de) Hochselektive butyrylcholinesterase inhibitoren zur behandlung und zur diagnose von demenz und alzheimers krankheit
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69429299D1 (de) Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE269705T1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
DE69722999D1 (de) Verwendung von Darifenacin zur Verbesserung der Wahrnehmung
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE302006T1 (de) Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen
DE59510674D1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen
ATE345138T1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition